Novel small type v rna programmable endonuclease systems
AssigneeBayer Aktiengesellschaft
InventorsAndre COHNEN, Florian RICHTER, Philipp KNYPHAUSEN, Andreas NEERINCX, Saskia Diana MARKERT, Christien BEDNARSKI, Sören TURAN, Theresa VOGT, Jaishree CHITTOOR
Life of this patent
Estimating the term…
Abstract
Described herein are novel systems for targeting, editing or manipulating DNA in a cell or cell free environment, using novel type V B-GEn.7 (SEQ ID NO: 1) and variants thereof, as well as methods and kits for manipulating DNA.
Claims14
A polypeptide that has at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, at least 99.5%, or 100% sequence identity with SEQ ID NO:
- 1.
(canceled)
A nucleic acid that has at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, at least 99.5% or 100% sequence identity with SEQ ID NO:
- 2 or SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.